Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

“Gilead’s restrictions on access to lenacapavir could allow the HIV epidemic to spread. This is the closest we have ever been ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...